$4.62-0.11 (-2.33%)
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer.
Bolt Biotherapeutics, Inc. in the Healthcare sector is trading at $4.62. Wall Street consensus targets $41.00 (2 analysts), implying a +787.4% move over the next 12 months. The stock is currently 37% below its 52-week high of $7.35, remaining 10.6% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated an...
Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of -51.23% and -98.27%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +10.70% and +150.00%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
BOLT) on Thursday reported a loss of $6.6 million in its fourth quarter. The Redwood City, California-based company said it had a loss of $3.84 per share. The company posted revenue of $2.5 million in the period.
Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +26.63% and +294.36%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
BOLT) on Wednesday reported a loss of $7.1 million in its third quarter. On a per-share basis, the Redwood City, California-based company said it had a loss of $3.72. The results exceeded Wall Street expectations.